Axoral Ketoconazole Tablets USP

Ketoconazole Tablets USP 200mg



Each uncoated tablet contains:

Ketoconazole USP 200 mg

Excipients q.s.



Ketoconazole is a synthetic imidazole dioxolaine derivative, active in vitro against dermatophytes, yeasts and other pathogenic fungi. In vitro Ketoconazole is fungicidal and, therefore, suppresses the formation of mycelia. In vivo, at therapeutic levels however, it is primarily fungistatic. Ketoconazole acts in the case of C. albicans by inhibiting lanosterol demethylation in the biosynthesis of ergosterol, resulting in cell membrane defects.



The absorption of Ketoconazole from the gastrointestinal tract is variable and increases with decreasing stomach pH. Mean peak plasma concentrations of about 3.5 micrograms/mL have been obtained 2 hours after administration of 200 mg by mouth.



AXORAL TABLETS is indicated for:

Treatment of superficial and deep mycoses:

-Systemic mycotic infections such as systemic candidiasis;

-Chronic and recurrent vaginal candidiasis not responding to topical treatment;

-Serious chronic infections of the skin, hair and nails caused by sensitive dermatophytes, e.g. Trichophyton rubrum, T. mentagrophytes, and/or yeasts (dermatomycoses, paronychia, serious chronic mucocutaneous candidiasis, etc.);

-When topical treatment is ineffective owing to the involvement of large areas of the skin, or lesions penetrating the deeper dermal layers, nails and hair.



AXORAL TABLETS are contraindicated in persons with a history of hypersensitivity to Ketoconazole.



Adult: The recommended starting dose is a single daily administration of 200mg (1 tablet). In very serious infections or where its clinical responsiveness is insufficient, the dose may be increased to 400mg (2 tablets) once daily.

Children: in children over 2 years of age, a single daily dose of 3.3 mg/kg is recommended. The tablets have not been studied in children under 2 years of age.

Treatment should be continued until indication the active fungal infection has subsided. Minimum treatment period for Candidiasis is one or two weeks.



In the event of accidental overdosage, supportive measures including gastric lavage with Sodium bicarbonate should be employed.



Gastrointestinal disturbances are the most frequently reported adverse effect following the oral administration of Ketoconazole. Nausea, vomiting, diarrhoea, constipation, abdominal pain and pruritis. Rarely headache, dizziness, impotence, somnolence, fever, chills, photophobia, gynecomastia, thrombocytopenia, leucopenia and hemolytic anemia.



Patients should be instructed to report any sign and symptoms which may suggest liver dysfunction so that appropriate biochemical testing can be done. Such signs and symptoms may include unusual fatigue, anorexia, nausea and vomiting, jaundice, dark urine and pale stools.



Drugs like Terfenadine, astemizole, mizolastine, cisapride, triazolam, oral midazolam, dofetllide, quinidine, pimozide, CYP3A4 metabolised HMG-Co A reductase inhibitors such as simvastatin and lovastatin should not be used during treatment with Ketoconazole.



Pregnancy: Ketoconazole is teratopenic in small, laboratory animals.
No studies are available on its use in pregnant women. Therefore it must not be administered during pregnancy.

Lactation: Since Ketoconazole is excreted in the milk, mothers who are under treatment should not breast feed.



36 months from the date of manufacturing.



Store in a cool, dry and dark place.

Keep all medicines out of reach of children.



Alu-Alu blister pack of 10 tablets in a carton with pack insert.


NAFDAC Reg. No: B4-5194


Manufactured in India by


C/1-49 & 36, Degam Road,

Industrial Township – Vapi 396 195


Sole Agent


13 Olowu Street, Ikeja,

Lagos, Nigeria.

Triflucon Fluconazole Capsules

Fluconazole Capsules 150 mg


Each Capsule Contains:

Fluconazole USP 150mg

Excipients Q.S

Approved colours used in empty capsule shell.



Fluconazole is a triazole antifungal drug which in sensitive fungi inhibits cytochrome P-450 dependent enzymes resulting in impairment of ergosterol synthesis in fungal cell membranes.

Fluconazole is well absorbed following oral administration, bioavailability from the oral route being 90% or more of that from the intravenous route. Peak plasma concentrations are reached within 1 to 2 hours of oral administration. Plasma concentrations are proportional to the dose over a range of 50 mg to 400 mg. Multiple dosing leads to increases in peak plasma concentrations; steady-state concentrations are reached in 6 to 10 days but may be attained on day 2 if a loading dose is given. The elimination half life of fluconazole is about 30 hours and is increased in patients with impaired renal function. Plasma protein binding is only about 12%. It has been shown in pharmacokinetic studies performed in children that fluconazole is cleared faster in children than in adults, with a half life of 23 hours. In children under the age of 1, the volume of distribution of fluconazole (950 mL/kg) is higher than in adults (700 mL/kg). Accumulation on multiple daily dosing is therefore less and steady state plasma levels are achieved faster than in adults. The half lives of fluconazole, in neonates, determined over the first 2 weeks of life are considerably longer than adult values with a mean of 74 hours at Day 1 and 47 hours at Day 13 of life. The volume of distribution is about 1200 mL/kg in neonates. Eighty percent or more of fluconazole is excreted unchanged in the urine about 11% is excreted as metabolites. Fluconazole clearance is proportional to creatinine clearance. There is no evidence circulating metabolites, but accumulation is significant over 15 days and concentrations may rise 2-3 fold. The long plasma elimination half-life (approximately 30 hours) provides the basis for once daily dosing in the treatment of systemic conditions, single dose therapy for vaginal candidiasis and once weekly dosing for other indications. Cases of super-infection with Candida species other than C. albicans, which are often inherently not susceptible to fluconazole (e.g., Candida krusei), have been reported. Such cases may require alternative antifungal therapy. Fluconazole has been shown not to affect testosterone plasma concentrations in males or steroid concentrations in females of child-bearing age.



Anti-infective therapy should be adjusted according to the results of cultures and laboratory studies. Fluconazole is administered by mouth or by intravenous infusion in similar doses.

Fluconazole is indicated for the treatment of the following conditions in adults and children

(1) Cryptococcal meningitis and maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS.

(2) Systemic candidiasis.

(3) Oropharyngeal and oesophageal candidiasis.

(4) Prevention of fungal infections in patients with malignancy who are predisposed to such infections as a result of cytotoxic chemotherapy and radiotherapy.

When systemic treatment is indicated and appropriate, fluconazole is used in the following conditions

(1) Vaginal candidiasis, acute or recurrent and prophylaxis to reduce the incidence of recurrent vaginal candidiasis.

(2) Candidial balanitis.

(3) Deematomycosis including tinea cruris, tinea corporis, tinea pedis, tinea unguium (onychomycosis), and dermal candida infection.



Hypersensitivity to fluconazole or any of the ingredients of the preparation. Concomitant administration of cisapride is contraindicated in patients receiving fluconazole. Concomitant administration of terfenadine is contra-indicated in patients receiving fluconazole at multiple doses of 400mg per day or higher based upon results of a multiple dose interaction study. Multiple dose therapy is contraindicated in patients with renal impairment

Pregnancy: Fluconazole should not be given to breast-feeding women, as fluconazole is found in breast milk at concentrations similar to plasma.



Use during pregnancy and lactation. Safety in pregnancy and lactation has not been established.

There are no adequate and well controlled studies which assessed the safety of fluconazole treatment in pregnant women. Congenital abnormalities in infants whose mothers were treated with fluconazole have been reported. The relationship between fluconazole use and these events are unclear.

Use in children: Insufficient evidence is available to establish safety and efficacy of fluconazole in children in the following conditions

(1) Vaginal candidiasis.

(2) Candidial balanitis.

(3) Dermatomycosis

Effects on Ability to Drive and Use Machines: Experience indicates that fluconazole therapy is unlikely to impair a patient’s ability to drive or use machinery.

Hepatic Function: Cases of serious hepatic toxicity including fatalities, have been associated with fluconazole therapy, primarily in patients with serious underlying medical conditions. In cases of fluconazole-associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, age or sex of patient has been observed. Hepatotoxicity may be reversible on discontinuation of therapy.
Patients who develop abnormal liver function tests during fluconazole therapy should be monitored for the development of more serious hepatic injury. If clinical signs or symptoms consistent with liver disease develop that may be attributable to fluconazole, fluconazole therapy should be discontinued. Less frequently, patients have developed rashes, pruritis, urticaria, dry skin, angioedema, abnormal odour, exfoliative cutaneous reactions, such as Steven-Johnson Syndrome and toxic epidermal necrolysis during fluconazole therapy. AIDS patients are more susceptible to the development of severe cutaneous reaction to many drugs. If patients with systemic fungal infections develop rashes, they should be closely monitored and if bullous lesions or erythema multiforme develop fluconazole therapy should be discontinued. Concomitant administration of fluconazole at doses lower than 400mg per day with terfenadine should be carefully monitored.

Dosage in Patients with Impaired Renal Function: Fluconazole should be used with caution in patients with impaired renal function. Eighty percent or more of fluconazole is excreted unchanged in the urine.

No adjustments in single dose therapy are necessary. In patients with renal impairment, multiple-dose therapy should be carefully monitored. An initial dose of 50 to 400 mg should be administered to patients (including children) with impaired renal function. After the loading dose, the daily dose (according to indication) should be based on the following:



Therapy for infections requiring multiple dose treatment should be continued until laboratory tests and clinical parameters indicate that active fungal infection has subsided. An insufficient duration of fluconazole therapy may lead to the recurrence of active infection. Maintenance therapy in patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal candidiasis is usually necessary to prevent relapse.

Use in Adults

(1) Cryptococcal meningis may be treated with an initial dose of fluconazole 400mg on the first day followed by 200mg once daily: This dose may be increased to 400mg daily, depending on the clinical response of the patient. The duration of therapy for cryptococcal meningitis is based on clinical and mycological response, but is usually 6-8weeks. Fluconazole may also be used in daily doses of 100 to 200 mg to prevent relapse following a primary course of antifungal therapy for acute cryptococcal meningitis in patients with AIDS.

(2) Systemic candidiasis may be treated with an initial dose of fluconazole 400mg on the first day followed by 200mg daily. The dose may be increased to 400 mg daily, depending on the clinical response of the patient. Duration of therapy for systemic candidiasis treatment is based on the clinical response of the patient

(3) For oropharyngeal candidiasis, the usual dose is 50 to 100mg once daily for 7-14 days. In patients with severely compromised immune function, treatment can be continued for longer periods if necessary. In patients with AIDS, after the patient receives a full course of primary therapy, fluconazole may be administered at a 150 mg once weekly dose in order to prevent a relapse of oropharyngeal candidiasis. For oesophageal candidiasis, the recommended dose is 200mg on the first day, followed by 100 mg to 200mg once daily. Doses of up to 400mg daily may be used based on medical judgment of the patient’s response to therapy. Patients with oesophageal candidiasis should be treated for a minimum of three weeks and for at least two weeks following resolution of symptoms.

(4) For the prevention of candidiasis, a fluconazole dosage of 50 mg to 400 mg once daily is recommended based on the patients risk for developing fungal infection. A dose of 400mg once daily has been used in patients who are at high risk of systemic infection e.g. patients who are anticipated to have profound or prolonged neutropenia. Fluconazole administration should commence several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 1000 cells per mm3.

(5) Fluconazole 150 mg should be administered as a single oral dose for vaginal candidiasis. A 150mg once monthly dose may be used to reduce the incidence of recurrent vaginal candidiasis. lndividualisation of the duration of therapy is necessary but ranges from 4-12 months. Some patients may require more frequent dosing.

(6) Fluconazole 150mg should be administered as a single oral dose, for the treatment of candida balanitis.

(7) For dermal infections including tinea cruris, pedis, corporis, and candida infections the recommended dosage is 150 mg once weekly. The recommended duration of therapy is normally 2 to 4 weeks. Tinea pedis may require treatment for up to 6 weeks.

The recommended dosage for tinea unguium is 150mg once weekly. Treatment should be continued until infected nail is replaced (uninfected nails grow in). Re-growth of fingernails and toenails normally require 3 to 6 months and up to 6 to 12 months respectively. However, growth rates may vary widely in individuals and by age. Nails occasionally remain disfigured after successful treatment of long term chronic infections.

Use in Elderly: Normal dosage recommendations should be adopted where there is no evidence of renal impairment.

Use in Children: As with similar infections in adults, the duration of fluconazole therapy is based on the clinical and mycological response. The maximum adult daily dosage should not be exceeded in children. Fluconazole is administered as a single daily dose.

(1) For the treatment of oropharyngeal candidiasis in children, the recommended fluconazole dosage is 6 mg/kg on the first day, followed by3 mg/kg once daily. To lower the likelihood of relapse, treatment should be administered for at least 2weeks.

(2) For the treatment of oesophageal candidiasis in children, the recommended fluconazole dosage is 6 mg/kg on the first day, followed by 3 mg/kg once daily. Based on medical judgment of the patient’s response, doses up to 12 mg/kg/day may be used. Patients with oesophageal candidiasis should be treated for a minimum of three weeks and for at least 2 weeks following the resolution of symptoms.

(3) For the treatment of systemic candidiasis and cryptococcal infection, the recommended dosage is 6-12 mg/kg/day, depending on the severity of the disease.

(4) For the prevention of fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following cytotoxic chemotherapy or radiotherapy, the dose should be 3-12 mg/kg daily, depending on the extent and duration of the induced neutropenia. For children with impaired renal function the daily dose should be reduced in accordance with the guidelines given for adults, dependent on the degree of renal impairment.

Use in children 4 weeks of age and younger: Fluconazole is excreted slowly in neonates. The first two weeks of life the same mg/kg dosing as in older children should be used but administered every 72 hours. The same dose should be given every 48 hours, during weeks 3 and 4 of life.



The most common side-effects associated with fluconazole are

Gastrointestinal: Abdominal pain, diarrhoea, nausea, vomiting, and flatulence. Abnormalities of hepatic, renal and haematological function have been observed during fluconazole therapy in some patients, particularly those with serious underlying diseases such as AIDS and cancer.

Central and Peripheral Nervous System: Headache

Dermatologic: Rash. If a rash develops which is considered attributable to fluconazole, further treatment with this agent should be stopped.

Liver/Biliary: Serious hepatic toxicity has been reported in patients with severe underlying disease. Rare cases of fatalities elevated alkaline phosphatase, elevated bilirubin, elevated SGPT, eleveted SGPT have been observed.



In subjects receiving warfarin, fluconazole has been shown to prolong prothrombin times. In patients receiving concomitant fluconazole and warfarin therapy, bleeding events (haematuria, bruising, epistaxis, gastrointestinal bleeding, and malaena), in association with increases in prothrombin time have been reported. The dose of anticoagulant should be carefully titrated and the prothrombin time carefully monitored in patients who are being treated concomitantly with fluconazole and coumarin medicines. Such patients requiring minor oral surgery and dental procedures should be carefully monitored. Fluconazole has been shown to prolong the serum half life of concomitantly administered oral sulphonylureas. Clinically significant interactions have not been observed with concomitant administration of fluconazole and oral contraceptives. Clinically significant interactions have not been observed with concomitant administration of fluconazole and cimetidine.

Benzodiazepines (Short Acting): There is a potentially relevant interaction between midazolam and fluconazole. Data clearly indicates that fluconazole influences the pharmacokinetics of midazolam which results in substantial increases in midazolam concentrations and its psychomotor effects. This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. If concomitant benzodiazepine therapy is necessary in patients receiving fluconazole therapy, a reduction of the benzodiazepine dosage should be considered and patients should be appropriately monitored.

No adverse effect has been seen on endogenous steroid levels or on ACTH stimulated cortisol response.

It is recommended that the cyclosporin plasma concentration levels be monitored in patients receiving fluconazole therapy. In a kinetic study in renal transplant patients cyclosporin concentrations were found to slowly increase following a 200 mg fluconazole dose. However, in another multiple dose study with 100mg daily, fluconazole did not affect cyclosporin levels in patients with bone marrow transplants. Administration of multiple dose of hydrochlorothiazide and fluconazole has resulted in clinically significant increases in plasma-fluconazole concentrations. Administration of phenytoin and fluconazoIe has resulted in clinically significant increases in phenytoin concentrations. Fluconazole may reduce the clearance of theophylline. Thus, the concomitant administration of fluconazole and theophylline may increase the risk of theophylline toxicity due to the fluconazole induced decrease in plasma theophylline clearance. Concomitant administration of rifampicin and fluconazole results in reduced plasma concentration of fluconazole.

Zidovudine: Increased plasma concentrations of zidovudine have been reported. An increase in zidovudine levels, probably caused by the decreased conversion of zidovudine to its major metabolite was observed during two kinetic studies. During one of the studies in AIDS or ARC patients, zidovudine levels were determined before and following a dosge of fluconazole 200 mg During the second study, a two-period, two- treatment, cross-over study in HIV patients, zidovudine levels were examined. On two occasions, 21 days apart, patients received zidovudine 200 mg every eight hours either with or without fluconazole 400mg daily for seven days. A significant increase in zidovudine AUC (74%) during concomitant administration of zidovudine and fluconazole was observed. It is recommended that patients receiving concomitant administration of zidovudine and fluconazole be monitored for the development of zidovudine related adverse reactions.

Terfenadine: The concomittant administration of fluconazole and terfenadine should be avoided because of the risk of cardiac arrhythmias. Increases in terfenadine concentrations following high doses of fluconazole have been associated with ECG abnormalities. Interaction studies have been performed, because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine. In one of the studies, a prolongation of the OTc interval was not observed, following a 200mg daily dose of fluconazole. In a second study, significant increases in terfenadine plasma levels were observed following a 400mg and 800mg daily dose of fluconazole. The concomitant administration of terfenadine and fluconazole at doses of 400mg or greater is contra-indicated. Patients receiving concomitant administration of fluconazole at doses lower than 400mg per day with terfenadine should be carefully monitored.

Rifabutin: Increases in plasma concentrations of rifabutin has been reported. Uveitis in patients receiving concomitant administration of fluconazole and rifabutin has been reported. Patients receiving concomitant administration of rifabutin and fluconazoIe shouId be carefully monitored.

Cisapride: The concomitant use of fluconazole with cisapride should be avoided because of the risk of cardiac arthythmias. Concurrent administration of fluconazole and cisapride could result in increased cisapride concentration and associated toxicity. In patients receiving concomitant fluconazole and cisapride therapy, cardiac events including torsade de pointes has been reported. The concomitant administration of cisapride is contra-indicated in patients receiving fluconazole.

Tacrolimus: There have been reports that an interaction exists when fluconazole is administered concomitantly with tacrolimus, resulting in increased plasma concentrations of tacrolimus. Nephrotoxicity has been reported in patients receiving concomitant administration of fluconazole and tacrolimus. Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored for changes in plasma concentrations of tacrolimus and/or nephro- and neurotoxicity. Fluconazole may interfere with the metabolism of astemizole or other medicines metabolised by the cytochrome P-450 system, presumably through inhibition of cytochrome P-450 (CYP3A4). This may account for the reported increases in plasma concentrations of these medicines. In the absence of definitive information, caution should be used when co-administering fluconazole. Patients should be carefully monitored.



Overdosage with fluconazole has been reported. In one case a 42 year-old patient infected with HIV developed hallucinations and exhibited paranoid behaviour after reportedly ingesting 8200mg of fluconazole. The patient was admitted to hospital and his condition resolved within 48 hours. The following events have been reported with an overdosage with fluconazole: Insomnia, Irritability, vomiting, diarrhoea, abdominal pain/cramps, anorexia, bulging fontanel, elevation of alkaline phosphatase and gamma glutamyl transpeptidase, increase in serum calcium, renal failure, fatigue, facial rash, skin erythema, generalised urticaria, arthralgia, itching, numbness of the tongue and distressed mood. As no clear pattern of overdosage adverse events was identified, it is not possible to relate fluconazole overdosage to a specific pattern of adverse events. In the advent of overdosage, symptomatic treatment (with supportive measures and gastric lavage if necessary) may be adequate. Fluconazole is largely excreted in the urine; forced diuresis would probably increase the elimination rate. A three hour haemodialysis session decreases plasma levels by approximately 50%.



Store in a cool and dry place. Protected from light.

Keep all medicines away from children.



10 blisters of 1 capsule in a carton.


Mfg. Lic. No.: G/l 479-A


NAFDAC Reg. No.: A4-6953


Manufactured by

Baroque Pharmaceuticals Pvt. Ltd.,

Sokhada-388620, Khambhat,

Anand, Gujarat, India.


Manufactured under license from

Novopharm Formulations (P) Ltd.,

105, Rajmandir, 62 Alkapuri Society,

R. C. Dutt Road, Vadodara 390007,

Gujarat, India.


Manufactured for

Tricare Pharma Limited

6 Yusuf Oyero Street, Off Demurin Street,

Ketu, Lagos, Nigeria

Festnystat Nystatin USP Tablet

(Nystatin Vaginal Inserts USP 100,000 IU)



Each uncoatad vaginal tablet contains:

Nystatin USP 100,000 IU

Excipients q.s.



Nystatin is an antifungal antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. It probably acts by binding to sterols in the cell membrane of the fungus with a resultant change in the membrane permeability allowing leakage of intracellular components.



Nystatin vaginal Tablets are indicated in the treatment of Trichomonal vaginitis, mixed vaginal infections, vaginal moniliasis, and candidal vaginitis.



To be avoided in patients with known hypersensitivity to any of the components of these tablets.


Special Precautions

In case of a hypersensitivity reaction, the drug should be immediately withdrawn and appropriate measures taken.


Adverse Effects

Failure of Contraceptive (Diaphragm) with vaginal pessaries. It should not be used concomitantly or rubber may be damaged. Prolonged use causes irritation.


Method of Administration

For vaginal infections in dosage of nystatin tablet once or twice daily to be inserted deep into the vagina for 14 days.



Jar of 100 Tablets.



Store in cool, dark & dry place.

Protect from light and moisture.

Keep medicines out of reach of children.


Manufactured by

Medico Remedies Pvt. Ltd.

Palgher, Maharashtra – 401 404.



Marketed by

Man Fes Pharma Company Nig. Ltd.

3, Belawa Street, Fegge,

Onitsha. Nigeria.